ATI355
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Spinal Cord Injury
Conditions
Acute Spinal Cord Injury
Trial Timeline
May 1, 2006 → Sep 1, 2011
NCT ID
NCT00406016About ATI355
ATI355 is a phase 1 stage product being developed by Novartis for Acute Spinal Cord Injury. The current trial status is completed. This product is registered under clinical trial identifier NCT00406016. Target conditions include Acute Spinal Cord Injury.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00406016 | Phase 1 | Completed |
Competing Products
20 competing products in Acute Spinal Cord Injury